Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

Q1 2025 Earnings Call Transcript April 16, 2025 Abbott Laboratories beats earnings expectations. Reported EPS is $1.09, ...

Johnson & Johnson’s electrophysiology unit struggled in the first quarter, as the company chases Medtronic and Boston ...

Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and ...

Abbott designed the Volt PFA catheter for maneuverability, efficient ablation and thermal risk mitigation, said Dr.

CEO Robert Ford noted that Abbott has 90 manufacturing locations worldwide, with plants close to customers, redundancy, and ...

Despite major product launches from diabetes rivals last year, Abbott’s diabetes unit brought in $1.8bn total Q1 sales to ...

Abbott Laboratories ABT reported first-quarter 2025 adjusted earnings per share (EPS) of $1.09, which beat the Zacks ...

Abbott Labs boosted its earnings in the first quarter and hinted that its full-year guidance might have gotten a lift were it ...

Abbott Laboratories reports strong Q1 2025 results with 8% organic growth, double-digit EPS gains, and robust Medical Devices performance.

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments. The healthcare products ...